CONFERENCE SERIES: Biomarkers and Diagnostics

Recorded at: XGen Congress

Digital Course: Sequencing-Based Molecular Diagnostics


Order DVDSequencing-Based Molecular Diagnostics DVD About this Product:
Translating a promising lead into an approved clinical diagnostic test is not for the faint of heart, especially if there are no regulatory guidelines to follow.  Many considerations must be faced in developing, validating, performing, and funding a diagnostic through to regulatory approval. NGS currently stands at this juncture. Learn from the trailblazers that are bridging the gap between research and the clinic. 



About this Product:
3 Presentations
Over 153 Slides
175 Minutes
Individual Copy: $345
Site License: $1380

Agenda At A Glance: 

Advancing the Promise of Personalized Management of Prostate Cancer Using Next-Generation Sequencing and Computer Science
Colin Collins Colin Collins, Ph.D., Senior Scientist, Vancouver Prostate Centre 

Biography: Dr. Colin Collins attended Western New England College and received his Ph.D. at the University of British Columbia, Vancouver, Canada in the Department of Medical Genetics. Since early 2009 Collins has been a visiting senior scientist at the Vancouver Prostate Centre and Director of the Microarray Facility, while continuing to hold his appointments at UCSF in the Department of Urology, and at Lawrence Berkeley National Laboratory. Collins’ current research is best described as translational genomics where mathematics, genomics, computer science, and clinical science converge in diagnostics and therapeutics. Collins invented and patented End Sequence Profiling (ESP), the forerunner of modern paired-end sequencing. Collins is on the Scientific Advisory Boards of the International Drug Discovery Science and Technology Conference (China), BIT Life Sciences Gene Conference (China), Genome British Columbia’s Molecular Lymphoma project, and Combimatrix Molecular Diagnostics. He has authored or coauthored approximately 80 peer-reviewed manuscripts, holds multiple patents, and has received numerous awards including the California Cancer Research Programs Cornelius L. Hopper Scientific Achievement Award for Innovation and the AACR Annual Meeting Best Abstracts Plenary Session. 
Developing Next Generation Sequencing Based Diagnostics for Implementation into the Clinical Laboratory
Karl Voelkerding Karl Voelkerding, M.D., Associate Professor of Pathology, University of Utah; Medical Director, Advanced Technology and Bioinformatics, ARUP Laboratories 

Biography: Dr. Karl Voelkerding received his medical degree from the University of Cincinnati College of Medicine in 1983.  He subsequently pursued postgraduate training in molecular biology and clinical pathology.  From 1990 to 2000, Dr. Voelkerding was a faculty member in the Department of Pathology and Laboratory Medicine at the University of Wisconsin-Madison.  Currently, Dr. Voelkerding is an Associate Professor of Pathology at the University of Utah and Medical Director for Advanced Technology and Bioinformatics at the ARUP Laboratories. Dr. Voelkerding is board certified in Clinical Pathology and Molecular Genetic Pathology.  In 2001, he served as President of the Association for Molecular Pathology.  Dr. Voelkerding's research interests include translation of nucleic acid based technologies into diagnostics with a current focus on complex genetic analyses by next generation sequencing which he is pursuing as Director of the ARUP Genomics Laboratory.

Developing a NGS Test for Carrier Screening for 568 Diseases
Stephen Kingsmore Stephen Kingsmore, D.Sc., Director, Center for Pediatric Genomic Medicine, Children’s Mercy Hospital 

Biography: Dr. Stephen F. Kingsmore joined Children’s Mercy Hospital, Kansas City, MO, in January 2011 to set up a new center that will make interpreted genome sequence information available to physicians, researchers and patients. Previously, Dr. Kingsmore the President of the National Center for Genome Resources, Santa Fe, New Mexico. Prior to this, Dr. Kingsmore was Chief Operating Officer of Molecular Staging Inc., Vice President of Research of CuraGen Corp. and Assistant Professor at the University of Florida. Dr. Kingsmore received M.B., Ch.B., B.A.O. and D.Sc. in molecular genetics from Queen's University Belfast. He completed residency in Internal Medicine and fellowship in Rheumatology at Duke. His research interests are genome analysis, systems surveys and individualized medicine.

About the Conference:
X-Gen Congress and Expo is the event for the genomics revolution, promoting the cross-fertilization of established and emerging technologies, along with exciting applications for next-generation sequencing. This year’s programming addresses the technological advances enabling faster and cheaper DNA/RNA mapping, creating genomic comparisons and accelerating genomic discoveries. It will also showcase next-generation sequencing platforms creating sequence reads of DNA fragments for genome variation studies, RNA for transcriptome studies, DNA-protein interactions for epigenetic studies, and chromosomal DNA of  large genome nucleotide variations for copy number studies.

Japan-Flag  Korea-Flag  China-Simplified-Flag  China-Traditional-Flag  

Final Days to Register 

Download Brochure

2013 XGEN Congress Download Form
2013 Final Brochure 

Stay Connected




View All Sponsors 

View Media Partners 

XGN Genome Bottle  

NGS for Drugs, Patients and Clinical Trials  

NGS Leaders